On October 21, 2024, Todd Harris, President and Chief Executive Officer of Tyra Biosciences Inc (TYRA, Financial), sold 62,720 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 1,355,927 shares of Tyra Biosciences Inc.
Tyra Biosciences Inc is focused on developing precision medicines for patients with genetically defined cancers. The company leverages its proprietary SNÃ…P platform to systematically discover and develop small molecules that target oncogenic drivers.
According to the filing, the shares were sold at a price of $27.28 each. This transaction has adjusted the insider's stake in the company significantly. Over the past year, Todd Harris has sold a total of 250,000 shares and has not made any purchases of the company's stock.
The recent sale is part of a broader trend observed within Tyra Biosciences Inc, where there have been no insider buys but 14 insider sells over the past year. This pattern of transactions provides insights into the insider sentiment towards the stock's performance and potential future movements.
As of the date of the sale, Tyra Biosciences Inc had a market cap of approximately $1.487 billion. The company's valuation metrics, such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are key indicators for investors assessing the company's stock value in relation to its earnings, sales, book value, and cash flow.
For further insights into the valuation of Tyra Biosciences Inc, investors might consider examining the GF Value, which provides an estimate of the intrinsic value of a stock based on historical multiples, adjusted for growth estimates.
This insider sale might influence the perceptions of current and potential investors, as insider transactions are often closely monitored for indications about the future direction of a company's stock price.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
